ESR1 and breast cancer: We rationalized GIV because of its known protumorigenic properties (outlined earlier in Results) and because we found it intriguing that the ER+ breast cancer cells typically silence this gene through alternative splicing (51), only to “borrow” it back from MSCs later in the bone marrow niche (this work).